Concepts (191)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Medically Uninsured | 5 | 2017 | 77 | 2.450 |
Why?
|
| Emergency Service, Hospital | 9 | 2020 | 1215 | 1.730 |
Why?
|
| Emergency Medicine | 3 | 2018 | 173 | 1.330 |
Why?
|
| Insurance Coverage | 3 | 2017 | 117 | 1.050 |
Why?
|
| Medicaid | 3 | 2017 | 252 | 0.970 |
Why?
|
| Patient Transfer | 2 | 2017 | 111 | 0.930 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 9 | 2015 | 327 | 0.840 |
Why?
|
| Diagnostic Errors | 3 | 2020 | 342 | 0.820 |
Why?
|
| Health Expenditures | 3 | 2017 | 134 | 0.690 |
Why?
|
| Aftercare | 3 | 2017 | 154 | 0.680 |
Why?
|
| Medical Overuse | 2 | 2018 | 24 | 0.670 |
Why?
|
| Patient Protection and Affordable Care Act | 3 | 2017 | 69 | 0.660 |
Why?
|
| Lung Neoplasms | 11 | 2015 | 1545 | 0.630 |
Why?
|
| Electronic Health Records | 3 | 2020 | 810 | 0.600 |
Why?
|
| Orthopedics | 3 | 2017 | 78 | 0.590 |
Why?
|
| Patient Discharge | 3 | 2017 | 512 | 0.590 |
Why?
|
| Emergency Medical Services | 3 | 2020 | 423 | 0.570 |
Why?
|
| Deinstitutionalization | 1 | 2017 | 2 | 0.540 |
Why?
|
| Emergency Services, Psychiatric | 1 | 2017 | 23 | 0.530 |
Why?
|
| Reimbursement Mechanisms | 1 | 2017 | 36 | 0.510 |
Why?
|
| Wounds and Injuries | 2 | 2017 | 395 | 0.500 |
Why?
|
| Medicare | 2 | 2017 | 440 | 0.490 |
Why?
|
| Health Information Exchange | 1 | 2016 | 10 | 0.490 |
Why?
|
| Stroke Rehabilitation | 1 | 2016 | 67 | 0.480 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 313 | 0.480 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2015 | 1281 | 0.450 |
Why?
|
| Choice Behavior | 1 | 2016 | 132 | 0.450 |
Why?
|
| Urinary Tract Infections | 2 | 2016 | 331 | 0.450 |
Why?
|
| Health Policy | 1 | 2017 | 227 | 0.450 |
Why?
|
| Appendicitis | 1 | 2016 | 132 | 0.450 |
Why?
|
| Safety-net Providers | 1 | 2016 | 88 | 0.440 |
Why?
|
| United States | 11 | 2024 | 11827 | 0.430 |
Why?
|
| Brain Ischemia | 1 | 2016 | 261 | 0.420 |
Why?
|
| Mental Health Services | 1 | 2017 | 272 | 0.420 |
Why?
|
| Gastroenteritis | 1 | 2016 | 307 | 0.420 |
Why?
|
| Information Dissemination | 1 | 2016 | 195 | 0.410 |
Why?
|
| Hypokalemia | 1 | 2014 | 40 | 0.410 |
Why?
|
| Program Evaluation | 1 | 2016 | 443 | 0.410 |
Why?
|
| Referral and Consultation | 1 | 2017 | 564 | 0.400 |
Why?
|
| Quality of Health Care | 1 | 2017 | 411 | 0.400 |
Why?
|
| Abdominal Pain | 1 | 2015 | 316 | 0.390 |
Why?
|
| Potassium | 1 | 2014 | 270 | 0.390 |
Why?
|
| Hyperkalemia | 1 | 2014 | 70 | 0.380 |
Why?
|
| Patient Readmission | 1 | 2016 | 424 | 0.380 |
Why?
|
| Diabetes Mellitus | 3 | 2016 | 893 | 0.370 |
Why?
|
| Radiation Oncology | 1 | 2012 | 28 | 0.360 |
Why?
|
| Hospitalization | 2 | 2018 | 1942 | 0.360 |
Why?
|
| Quality Improvement | 1 | 2017 | 708 | 0.330 |
Why?
|
| Health Services Accessibility | 1 | 2017 | 701 | 0.330 |
Why?
|
| Mental Disorders | 1 | 2018 | 909 | 0.310 |
Why?
|
| Mass Screening | 1 | 2016 | 825 | 0.310 |
Why?
|
| Heart Arrest | 1 | 2014 | 380 | 0.300 |
Why?
|
| Odds Ratio | 3 | 2017 | 1236 | 0.300 |
Why?
|
| Middle Aged | 16 | 2018 | 28911 | 0.290 |
Why?
|
| Texas | 4 | 2018 | 3629 | 0.280 |
Why?
|
| Pneumonectomy | 5 | 2013 | 151 | 0.280 |
Why?
|
| Asthma | 1 | 2016 | 927 | 0.270 |
Why?
|
| Humans | 31 | 2024 | 131967 | 0.270 |
Why?
|
| Aged | 15 | 2018 | 21279 | 0.270 |
Why?
|
| Male | 19 | 2024 | 65357 | 0.240 |
Why?
|
| Adult | 13 | 2024 | 31734 | 0.240 |
Why?
|
| Multivariate Analysis | 4 | 2018 | 1406 | 0.240 |
Why?
|
| Health Care Reform | 2 | 2017 | 52 | 0.230 |
Why?
|
| Insurance, Health | 2 | 2016 | 140 | 0.220 |
Why?
|
| Female | 19 | 2024 | 71316 | 0.210 |
Why?
|
| Cost Savings | 1 | 2024 | 78 | 0.210 |
Why?
|
| Lung | 1 | 2012 | 1571 | 0.210 |
Why?
|
| HIV Infections | 1 | 2016 | 2042 | 0.200 |
Why?
|
| Databases, Factual | 2 | 2018 | 1224 | 0.190 |
Why?
|
| Logistic Models | 2 | 2018 | 1838 | 0.190 |
Why?
|
| Forecasting | 2 | 2015 | 361 | 0.180 |
Why?
|
| Retrospective Studies | 11 | 2017 | 17703 | 0.180 |
Why?
|
| Small Cell Lung Carcinoma | 2 | 2011 | 32 | 0.170 |
Why?
|
| Risk Factors | 8 | 2016 | 10998 | 0.150 |
Why?
|
| Lymphatic Metastasis | 4 | 2015 | 433 | 0.140 |
Why?
|
| Adolescent | 4 | 2018 | 21008 | 0.140 |
Why?
|
| Neoplasm Staging | 5 | 2013 | 1325 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 2 | 2016 | 1307 | 0.130 |
Why?
|
| Criminal Law | 1 | 2017 | 15 | 0.130 |
Why?
|
| Trauma Severity Indices | 1 | 2017 | 87 | 0.130 |
Why?
|
| Refusal to Treat | 1 | 2017 | 9 | 0.130 |
Why?
|
| Fees and Charges | 1 | 2017 | 10 | 0.130 |
Why?
|
| Skilled Nursing Facilities | 1 | 2016 | 8 | 0.130 |
Why?
|
| Organizational Innovation | 1 | 2017 | 44 | 0.130 |
Why?
|
| Appointments and Schedules | 1 | 2017 | 49 | 0.130 |
Why?
|
| Ambulances | 1 | 2016 | 21 | 0.130 |
Why?
|
| Diagnosis-Related Groups | 1 | 2016 | 28 | 0.130 |
Why?
|
| Patient Simulation | 1 | 2017 | 40 | 0.120 |
Why?
|
| Uncompensated Care | 1 | 2016 | 12 | 0.120 |
Why?
|
| Gallbladder Diseases | 1 | 2015 | 26 | 0.120 |
Why?
|
| Aged, 80 and over | 7 | 2016 | 6922 | 0.120 |
Why?
|
| Confidentiality | 1 | 2016 | 104 | 0.120 |
Why?
|
| Medical History Taking | 1 | 2015 | 109 | 0.110 |
Why?
|
| Hospitals, Urban | 1 | 2015 | 99 | 0.110 |
Why?
|
| Program Development | 1 | 2016 | 181 | 0.110 |
Why?
|
| Lost to Follow-Up | 1 | 2014 | 32 | 0.110 |
Why?
|
| Bone Diseases | 1 | 2014 | 44 | 0.110 |
Why?
|
| Young Adult | 3 | 2018 | 10108 | 0.110 |
Why?
|
| Hypercholesterolemia | 1 | 2016 | 234 | 0.110 |
Why?
|
| Potassium Chloride | 1 | 2014 | 45 | 0.110 |
Why?
|
| Anticholesteremic Agents | 1 | 2016 | 241 | 0.100 |
Why?
|
| Urban Population | 1 | 2016 | 281 | 0.100 |
Why?
|
| Patient Safety | 1 | 2018 | 447 | 0.100 |
Why?
|
| Guideline Adherence | 1 | 2016 | 393 | 0.100 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2012 | 393 | 0.100 |
Why?
|
| Public Health | 1 | 2016 | 277 | 0.100 |
Why?
|
| Antihypertensive Agents | 1 | 2016 | 422 | 0.100 |
Why?
|
| Diabetes Complications | 2 | 2013 | 199 | 0.100 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 1519 | 0.100 |
Why?
|
| Cognition | 1 | 2018 | 845 | 0.100 |
Why?
|
| Lymph Nodes | 1 | 2015 | 377 | 0.100 |
Why?
|
| Substance-Related Disorders | 1 | 2017 | 491 | 0.100 |
Why?
|
| Hypoglycemic Agents | 1 | 2016 | 475 | 0.090 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 895 | 0.090 |
Why?
|
| Bone and Bones | 1 | 2014 | 300 | 0.090 |
Why?
|
| Mediastinum | 1 | 2012 | 46 | 0.090 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2012 | 155 | 0.090 |
Why?
|
| Age Factors | 2 | 2016 | 2869 | 0.090 |
Why?
|
| Breast Implants | 1 | 2011 | 30 | 0.090 |
Why?
|
| Radiosurgery | 1 | 2013 | 135 | 0.090 |
Why?
|
| Carcinoma, Large Cell | 1 | 2011 | 6 | 0.090 |
Why?
|
| Hospital Mortality | 1 | 2016 | 1076 | 0.090 |
Why?
|
| Neoplasm, Residual | 1 | 2012 | 137 | 0.090 |
Why?
|
| Tumor Burden | 1 | 2012 | 239 | 0.090 |
Why?
|
| Mammaplasty | 1 | 2011 | 44 | 0.090 |
Why?
|
| Lymph Node Excision | 1 | 2012 | 171 | 0.090 |
Why?
|
| Surveys and Questionnaires | 2 | 2024 | 4058 | 0.090 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2011 | 40 | 0.080 |
Why?
|
| Biocompatible Materials | 1 | 2011 | 122 | 0.080 |
Why?
|
| Collagen | 1 | 2011 | 289 | 0.080 |
Why?
|
| Neoadjuvant Therapy | 1 | 2012 | 407 | 0.080 |
Why?
|
| Patient Selection | 1 | 2013 | 726 | 0.070 |
Why?
|
| Myocardium | 1 | 2014 | 876 | 0.070 |
Why?
|
| Stroke | 1 | 2016 | 1049 | 0.070 |
Why?
|
| Electrocardiography | 1 | 2014 | 984 | 0.070 |
Why?
|
| Early Detection of Cancer | 1 | 2012 | 418 | 0.070 |
Why?
|
| Hypertension | 1 | 2016 | 1362 | 0.070 |
Why?
|
| Ferric Compounds | 1 | 2007 | 39 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2012 | 1255 | 0.060 |
Why?
|
| Risk Assessment | 1 | 2016 | 3708 | 0.060 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 3843 | 0.060 |
Why?
|
| Time Factors | 1 | 2016 | 6285 | 0.060 |
Why?
|
| Neoplasm Metastasis | 1 | 2009 | 710 | 0.060 |
Why?
|
| Image Enhancement | 1 | 2007 | 173 | 0.060 |
Why?
|
| Antibodies | 1 | 2007 | 358 | 0.060 |
Why?
|
| Contrast Media | 1 | 2007 | 492 | 0.050 |
Why?
|
| Infant, Newborn | 1 | 2016 | 8604 | 0.050 |
Why?
|
| Follow-Up Studies | 4 | 2015 | 5298 | 0.050 |
Why?
|
| Proportional Hazards Models | 3 | 2011 | 1406 | 0.050 |
Why?
|
| Survival Analysis | 3 | 2011 | 1522 | 0.050 |
Why?
|
| Child, Preschool | 1 | 2016 | 15066 | 0.040 |
Why?
|
| SEER Program | 2 | 2011 | 210 | 0.040 |
Why?
|
| Safety Management | 1 | 2020 | 111 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2011 | 3135 | 0.040 |
Why?
|
| Attitude of Health Personnel | 1 | 2024 | 721 | 0.040 |
Why?
|
| T-Lymphocytes | 1 | 2007 | 1790 | 0.030 |
Why?
|
| Survival Rate | 2 | 2013 | 2154 | 0.030 |
Why?
|
| Treatment Outcome | 4 | 2013 | 13011 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2007 | 3928 | 0.030 |
Why?
|
| Demography | 1 | 2014 | 243 | 0.030 |
Why?
|
| Matched-Pair Analysis | 1 | 2013 | 28 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2014 | 773 | 0.020 |
Why?
|
| Mastectomy | 1 | 2011 | 75 | 0.020 |
Why?
|
| Propensity Score | 1 | 2013 | 266 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2011 | 155 | 0.020 |
Why?
|
| Vinblastine | 1 | 2010 | 55 | 0.020 |
Why?
|
| Carboplatin | 1 | 2010 | 80 | 0.020 |
Why?
|
| Mediastinal Neoplasms | 1 | 2010 | 40 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2010 | 134 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2010 | 353 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2011 | 910 | 0.020 |
Why?
|
| Cisplatin | 1 | 2010 | 286 | 0.020 |
Why?
|
| Reoperation | 1 | 2011 | 844 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 1261 | 0.020 |
Why?
|
| Length of Stay | 1 | 2013 | 1400 | 0.020 |
Why?
|
| CD5 Antigens | 1 | 2007 | 33 | 0.020 |
Why?
|
| Particle Size | 1 | 2007 | 137 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 2007 | 314 | 0.020 |
Why?
|
| Recurrence | 1 | 2010 | 1487 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2011 | 1695 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2007 | 772 | 0.010 |
Why?
|
| Cell Survival | 1 | 2007 | 854 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2007 | 1146 | 0.010 |
Why?
|
| Incidence | 1 | 2011 | 3352 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2010 | 1357 | 0.010 |
Why?
|
| Models, Biological | 1 | 2007 | 1396 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2011 | 5122 | 0.010 |
Why?
|
| Prognosis | 1 | 2011 | 4961 | 0.010 |
Why?
|
| Cytokines | 1 | 2007 | 1354 | 0.010 |
Why?
|
| Rats | 1 | 2007 | 3462 | 0.010 |
Why?
|
| Animals | 1 | 2007 | 34460 | 0.000 |
Why?
|